Rituximab-treated membranous lupus nephritis: Clinical outcome and effects on electron dense deposits

Annals of the Rheumatic Diseases

Volumn 70, Issue 6, 2011, Pages 1172-1173

  Jónsdóttir, Thórunn ^a   Sundelin, Birgitta ^a   Henriksson, Elisabet Welin ^a   Van Vollenhoven, Ronald F ^a   Gunnarsson, Iva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CD19 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOCORTICOID; PREDNISOLONE; RITUXIMAB;

ADULT; ALBUMIN BLOOD LEVEL; ALBUMINURIA; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; PROTEINURIA; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; URINE SEDIMENT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR BASEMENT MEMBRANE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MICROSCOPY, ELECTRON; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955804762     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.129288     Document Type: Letter

References (9)

1. Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol 2009;5:212-20.
2. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13. (Pubitemid 40216314) (Pubitemid 40216314)
3. Gunnarsson I, Sundelin B, Jónsdóttir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72. (Pubitemid 46608651) (Pubitemid 46608651)
4. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
5. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242) (Pubitemid 13221242)
6. Churg JBJ, Glassock RJ. Renal disease: classification and atlas of glomerular diseases. 2nd edn. New York, NY: Igaku-Shoin, 1995.
7. Austin HA, III, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75:382-91. (Pubitemid 13005770) (Pubitemid 13005770)
8. Yee CS. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300-5.
9. Furie RA, Looney R, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III lunar study. Arthritis Rheum 2009;60(Suppl. 1):S429.